Discovery Strategies to Maximize the Clinical Potential of T-Cell Engaging Antibodies for the Treatment of Solid Tumors

T-cell Engaging bispecific antibodies (TcEs) that can re-direct cytotoxic T-cells to kill cancer cells have been validated in clinical studies. To date, the clinical success with these agents has mainly been seen in hematologic tumor indications. However, an increasing number of TcEs are currently b...

Descripción completa

Detalles Bibliográficos
Autores principales: Voynov, Vladimir, Adam, Paul J., Nixon, Andrew E., Scheer, Justin M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7709135/
https://www.ncbi.nlm.nih.gov/pubmed/33217946
http://dx.doi.org/10.3390/antib9040065

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7709135/
https://www.ncbi.nlm.nih.gov/pubmed/33217946
http://dx.doi.org/10.3390/antib9040065

Ejemplares similares